'Statins' linked to improved survival in kidney transplant recipients

"Statin therapy is well established for the primary and secondary prevention of cardiovascular disease in the general population, but its effectiveness in patients with kidney disease is unclear," comments Dr. Rainer Oberbauer of the Medical University of Vienna, one of the study authors. "We showed that statin therapy was indeed associated with a lower risk of death in renal transplant recipients."

The study included data on 2,041 patients receiving their first kidney transplant between 1990 and 2003. At the time of transplantation, about 15 percent of the patients were taking statin drugs to reduce their cholesterol levels. Patient survival and survival of the transplanted kidney were compared for patients who were and were not taking statins.

Overall, survival was somewhat better for patients on statin treatment. At 12 years' follow-up, 73 percent of statin-treated patients were alive, compared to 64 percent of patients not taking statins.

An important part of the study was the use of sophisticated statistical analyses to adjust for potentially confounding variables—including the fact that patients taking statins had more cardiovascular risk factors and pre-existing cardiovascular disease. The results showed a significantly lower risk of death in patients taking statins—36 percent lower than in nonusers.

Statin treatment had no effect on survival of the transplanted kidney (graft survival). In both groups, about 70 percent of the transplanted kidneys were functioning after 12 years.

Kidney disease is a major risk factor for cardiovascular disease. Sixty percent of patients with kidney transplants die of cardiovascular disease, compared to 40 percent of the general population.

However, for several reasons, it has been unclear whether cholesterol-lowering statin treatment reduces cardiovascular risks in patients with kidney disease, according to Dr. Oberbauer. In a "risk factor paradox," higher cholesterol levels may be linked to improved survival for patients with end-stage renal disease (loss of kidney function requiring dialysis or transplantation). Studies of statin treatment in dialysis and kidney transplant patients have yielded conflicting results. Most other trials of statins have excluded patients with kidney disease.

"We now show that statin use in renal transplant recipients is associated with longer survival," says Dr. Oberbauer. However, he emphasizes that the observational study does not permit any cause-and-effect conclusions: "The proof that statin use prolongs life can only be accomplished in a randomized controlled trial."

Source: American Society of Nephrology

Therapy helps hard-to-transplant get a new kidney
(AP) -- Nearly one in three patients who need a kidney transplant may never get one because their bodies are abnormally primed to attack a donated organ. Now doctors are trying new ways to outwit the immune system and save more of those so-called "highly sensitized" patients - often with kidneys donated by living donors, considered the optimal kind.
Research suggests doctors should consider kidney-sparing surgery
A study of almost 1,500 kidney cancer patients treated at Memorial Sloan Kettering Cancer Center suggests that surgery to spare as much kidney tissue as possible may improve overall survival in patients who also have reduced kidney function at the time their cancer is diagnosed. The finding is significant because both kidney cancer and decreased kidney function appear to be increasing.
Depressed dialysis patients more likely to be hospitalized or die
Dialysis patients diagnosed with depression are nearly twice as likely to be hospitalized or die within a year than those who are not depressed, a UT Southwestern Medical Center researcher has found.
Hormone level may reflect mortality risk among dialysis patients
A new study suggests that monitoring levels of a hormone called fibroblast growth factor 23 (FGF-23) may provide information crucial to the treatment of patients with kidney failure. In the Aug. 7 New England Journal of Medicine, researchers from Massachusetts General Hospital (MGH) report that patients with elevated levels of FGF-23 when beginning hemodialysis had a significantly increased risk of death within the first year of treatment, regardless of whether they had other risk factors. The study also found evidence that FGF-23 levels may differ between racial groups, which may relate to observed disparities in survival of dialysis patients.
Simple lab test for bone disease linked to risk of death in dialysis patients
Among patients receiving dialysis for chronic kidney disease (CKD), high levels of alkaline phosphatase—a routinely measured laboratory marker of bone disease—may signal an increased risk of death, reports a study in the November Journal of the American Society of Nephrology (JASN).
Heart attack not a death sentence
Survivors of cardiac arrest who received intensive care can expect long-term quality of life at reasonable expense to the health care system. Research published today in BioMed Central's open access journal Critical Care is the first to show that the allocation of resources to the treatment of heart attack patients is equally as justified as the treatment of other intensive care patient groups.
As rates rise, researchers find better way to identify melanoma
University of Rochester Medical Center researchers found a new protein produced excessively in malignant melanoma, a discovery that is particularly relevant as skin cancer rates climb dramatically among young women.
New protocol streamlines therapy that makes more kidney transplants possible
A new therapy developed at Cedars-Sinai Medical Center improves transplant rates and outcomes for patients awaiting living- and deceased-donor kidney transplantation, according to a study published in the July 17 issue of the New England Journal of Medicine.

'Statins' linked to improved survival in kidney transplant recipients

Related stories:

News discussion: